PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2012 THE 2012 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 Ja
Tablets-au.com Available ED Pharmacy is an 1st. pharmacy providing a individual service to the community in Australia. Over 80,000 extremely satisfied customers! We're your medication drug store kamagra australia and have provided trusted service to families in Australia for over 15 years.
Microsoft word - mrsa on the rise06-07.doc(Methicillin -Resistant Staphylococcus Aureus)
Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that causes
infections in the body. MRSA infection is an infection with a strain of Staphylococcus
aureus bacteria that is resistant to antibiotics known as beta-lactams.1 These commonly
used antibiotics include methicillin, amoxicillin, and penicillin.
Most MRSA infections occur in people with weak immune systems, usually patients in
hospitals and long- term care facilities. MRSA infections in hospitalized patients are
known as healthcare-associated (HA-MRSA).1 MRSA infections in people not
considered high-risk in the community are known as community-associated MRSA (CA-
MRSA).1 Poor hygiene, crowded living conditions, athletes who share equipment,
prisoners, and children in daycare facilities are considered risk factors for MRSA.
Unfortunately, there has been a recent increase of both community and hospital
acquired MRSA. Some have speculated that the increase may be due to the
inappropriate use of third-generation cephalosporins,2 while others suggested
widespread use of quinolones is responsible.3
The standard laboratory gram-positive susceptibility testing panels list vancomycin and
linezolid as antibiotics to which MRSA is sensitive.4 Vancomycin has long been
considered the gold standard for treating MRSA infections because vancomycin-
resistant staphylococci are rare.4 Unfortunately, when vancomycin is used as single
drug therapy to treat MRSA infections, cure rates in serious infections has been very
disappointing (avg.40% failure).4 In treating nonserious MRSA infections, such as
wound, skin and urinary tract infections (UTIs), in addition to slow cure rates and failure
vancomycin is practically and economically burdensome. Because there is no oral form,
a patient for whom vancomycin is prescribed must be infused (IV or infusaport).
Additionally, to avoid toxicity, blood levels must be monitored regularly. Linezolid, an oral
drug that most MRSA isolates test sensitive carries a risk of hematological
abnormalities, including myclosuppression and thrombocytopenia.4 Linezolid, like
vancomycin, is extremely economically burdensome. So in response to alternatives to
vancomycin and linezolid new approaches are being investigated.
One option for clinicians to consider is rifampin combination therapy; if the patient has
a serious staphylococcal infection.4 Although rifampin is ineffective as a single-drug
therapy for treating staph infections, numerous studies have shown that when rifampin is
combined with vancomycin, trimethoprin-sulfamethoxazole, mineocycline, or
ciprofloxacin the clinical outcomes are markedly improved.4
Unfortunately, no treatment guarantees clinical success. This article in no way is
recommending a specific treatment , rather it is hoped this material will prompt
discussions and awareness among the medical community that will in some small way
improve patient care and lessen resistant staphylococci.
“MRSA infection” ,www.nlm.nih.gov/medlineplus/ency/article/007261, updated by Kenneth Wener M.D. Fukatsu K, Saito H, Matsuda T, Ikeda S, Furukawa S, Muto T, influences of type & duration of antimicrobial Prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg Dec.1997, 132-11320-1325 Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmel Y, Fluoroquinolones and the risk for MRSA is hospitalized patients, Emerg Infect Dis. November 2003,9:1415-1422 “ No mercy for MRSA” Medical Laboratory Observer by Dennis L. Wegner PhD Jan 2005 pg 26-29
International Journal of COPD open access to scientific and medical researchClinical pathway for acute exacerbations of chronic obstructive pulmonary disease: method This article was published in the following Dove Press journal: International Journal of COPD28 June 2011Number of times this article has been viewed Background: Randomized controlled trials, evidence-based medicine, clinical